检索历史 清除

玻璃体腔注射抗VEGF药物治疗早产儿视网膜病变(ROP)是目前研究热点,其用于治疗Ⅰ区ROP可取得明确疗效.目前应用于临床的抗VEGF药物包括贝伐单抗、雷珠单抗、阿柏西普、康柏西普等.但近年多项研究证实相较于传统激光光凝治疗,抗VEGF药物治疗ROP复发率升高,复发时间更迟,应延长随访期及可能需要重复注射药物.目前由于缺乏大规模前瞻性临床研究,多种抗VEGF药物治疗ROP的复发率、复发时间窗、危险因素和治疗方法等尚无明确定论.抗VEGF药物治疗ROP还需积累更多循证医学证据.

Intravitreal injection of anti-VEGF drugs for the treatment of retinopathy of prematurity (ROP) is a hot topic of research,and it can be used to treat the ROP (Ⅰ zone).The current anti-VEGF drugs include bevacizumab,ranibizumab,aflibercept and conbercept,etc.However,in recent years,several studies have confirmed that anti-VEGF drugs have an increased recurrence rate and a longer recurrence time than conventional laser photocoagulation therapy.The follow-up period should be extended and repeated injections may be required.Due to the lack of large-scale prospective clinical studies,the recurrence rate,time window of recurrence,risk factors and treatment methods of various anti-VEGF drugs for ROP are still unclear.Anti-VEGF drugs in the treatment of ROP needs to accumulate more evidence-based medical evidence.